| abstract |
The present invention relates to a selective 5-HT1A antagonist of the general formula wherein R1 is propyl or cyclobutyl; R2 is isopropyl, tert-butyl or cycloalkyl; R3 is hydrogen; and R4 is hydrogen or methyl, and a selective h5-HT1B antagonist or partial agonist of the formula wherein X is CH or O; R1 is hydrogen, alkyl or cycloalkyl; R2 is hydrogen or halo, alkyl or alkoxy; R3 is a product comprising the combination of morpholino, morpholinocarbonyl, 4-oxo-piperidino, trifluoromethyl or carbamoyl, the pharmaceutical composition comprising the combination and their use. HE |